Evidence map›Paper›PMID 25881247›Full record

ArticleBMC medical genomics2015

Integrative analysis of survival-associated gene sets in breast cancer.

Frederick S Varn, Matthew H Ung, Shao Ke Lou, Chao Cheng

Open access · goldAbstract read
In one paragraph

Article in BMC medical genomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ERFASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Frederick S VarnDepartment of Genetics, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, 03755, USA. Frederick.S.Varn.Jr.GR@dartmouth.edu.
Matthew H UngDepartment of Genetics, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, 03755, USA. Matthew.H.Ung.GR@dartmouth.edu.
Shao Ke LouDepartment of Genetics, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, 03755, USA. Shaoke.Lou@dartmouth.edu.
Chao ChengDepartment of Genetics, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, 03755, USA. chao.cheng@dartmouth.edu.
Dartmouth College · US

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Steven D Leach · 1985 to 2026
$91.3M
Quantitative Biology Research InstituteP20GM103534 · NIGMS · DARTMOUTH COLLEGE · PI AMOS, CHRISTOPHER I. · 2012 to 2016
$8.6M
Molecular and Cellular Biology at DartmouthT32GM008704 · NIGMS · DARTMOUTH COLLEGE · PI COMPTON, DUANE A. · 1998 to 2018
$6.8M
NCI NIH HHS P30 CA023108NIGMS NIH HHS GM103534NIGMS NIH HHS P20 GM103534NIGMS NIH HHS T32 GM008704
6 · The paper itself

Abstract

backgroundPatient gene expression information has recently become a clinical feature used to evaluate breast cancer prognosis. The emergence of prognostic gene sets that take advantage of these data has led to a rich library of information that can be used to characterize the molecular nature of a patient's cancer. Identifying robust gene sets that are consistently predictive of a patient's clinical outcome has become one of the main challenges in the field.

methodsWe inputted our previously established BASE algorithm with patient gene expression data and gene sets from MSigDB to develop the gene set activity score (GSAS), a metric that quantitatively assesses a gene set's activity level in a given patient. We utilized this metric, along with patient time-to-event data, to perform survival analyses to identify the gene sets that were significantly correlated with patient survival. We then performed cross-dataset analyses to identify robust prognostic gene sets and to classify patients by metastasis status. Additionally, we created a gene set network based on component gene overlap to explore the relationship between gene sets derived from MSigDB. We developed a novel gene set based on this network's topology and applied the GSAS metric to characterize its role in patient survival.

resultsUsing the GSAS metric, we identified 120 gene sets that were significantly associated with patient survival in all datasets tested. The gene overlap network analysis yielded a novel gene set enriched in genes shared by the robustly predictive gene sets. This gene set was highly correlated to patient survival when used alone. Most interestingly, removal of the genes in this gene set from the gene pool on MSigDB resulted in a large reduction in the number of predictive gene sets, suggesting a prominent role for these genes in breast cancer progression.

conclusionsThe GSAS metric provided a useful medium by which we systematically investigated how gene sets from MSigDB relate to breast cancer patient survival. We used this metric to identify predictive gene sets and to construct a novel gene set containing genes heavily involved in cancer progression.

Indexed as

Gene Expression ProfilingAlgorithmsArea Under CurveBreast NeoplasmsDatabases, GeneticDisease ProgressionFemaleGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansNeoplasm MetastasisNeoplasmsPrognosisProgramming LanguagesProportional Hazards ModelsSurvival Analysis

Identifiers

PMID25881247
PMCPMC4359519
OpenAlexW2026918499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.